Charles Duncan
Stock Analyst at Cantor Fitzgerald
(4.38)
# 304
Out of 4,759 analysts
250
Total ratings
46.06%
Success rate
19.69%
Average return
Main Sectors:
Stocks Rated by Charles Duncan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ACAD ACADIA Pharmaceuticals | Reiterates: Overweight | $28 | $17.56 | +59.45% | 21 | Feb 27, 2025 | |
| JAZZ Jazz Pharmaceuticals | Downgrades: Neutral | $140 → $150 | $138.81 | +8.06% | 6 | Feb 26, 2025 | |
| AXSM Axsome Therapeutics | Reiterates: Overweight | $153 | $122.17 | +25.24% | 22 | Feb 19, 2025 | |
| GHRS GH Research | Initiates: Overweight | $14 | $10.50 | +33.33% | 1 | Feb 13, 2025 | |
| DRUG Bright Minds Biosciences | Initiates: Overweight | n/a | $34.50 | - | 1 | Jan 10, 2025 | |
| BHVN Biohaven | Reiterates: Overweight | n/a | $29.86 | - | 17 | Dec 17, 2024 | |
| STOK Stoke Therapeutics | Reiterates: Overweight | n/a | $8.01 | - | 7 | Dec 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Overweight | $51 → $58 | $33.67 | +72.26% | 8 | Oct 30, 2024 | |
| ALKS Alkermes | Maintains: Overweight | $48 → $43 | $34.35 | +25.18% | 5 | Oct 25, 2024 | |
| CYTK Cytokinetics | Reiterates: Overweight | n/a | $43.43 | - | 7 | Oct 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $15.27 | - | 15 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $130 | $131.24 | -0.94% | 21 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $155 | $113.04 | +37.12% | 9 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $11.92 | - | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $3.74 | - | 5 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 | $16.69 | +109.71% | 6 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $13 | $4.85 | +168.04% | 5 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $7.29 | - | 6 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $0.43 | - | 2 | Jul 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $6.83 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $1.51 | - | 3 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $34 | $21.96 | +54.83% | 9 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $52 → $50 | $33.28 | +50.24% | 3 | Oct 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $5 | $5.42 | -7.75% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $0.47 | +751.43% | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $4 | $1.39 | +187.77% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $58 | $36.50 | +58.90% | 3 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $110 | $1.19 | +9,143.70% | 4 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $80 | $4.58 | +1,646.72% | 5 | Aug 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $3 | $1.17 | +157.51% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $16 → $11 | $8.67 | +26.87% | 2 | Dec 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $12 | $6.88 | +74.42% | 2 | Nov 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $146 → $168 | $8.34 | +1,914.39% | 6 | Jun 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $2.57 | +678.21% | 1 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $200 | $15.39 | +1,199.50% | 3 | Feb 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $4 | $0.52 | +669.97% | 3 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $24 | $2.81 | +754.09% | 1 | Oct 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $372 → $144 | $1.95 | +7,284.62% | 6 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $3 → $4 | $1.73 | +131.21% | 2 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $408 → $480 | $4.92 | +9,656.10% | 4 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $35 → $39 | $60.98 | -36.04% | 4 | May 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $15 | $55.40 | -72.92% | 4 | Feb 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $1.04 | - | 3 | Nov 15, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $180 | $5.57 | +3,131.60% | 1 | Oct 9, 2017 |
ACADIA Pharmaceuticals
Feb 27, 2025
Reiterates: Overweight
Price Target: $28
Current: $17.56
Upside: +59.45%
Jazz Pharmaceuticals
Feb 26, 2025
Downgrades: Neutral
Price Target: $140 → $150
Current: $138.81
Upside: +8.06%
Axsome Therapeutics
Feb 19, 2025
Reiterates: Overweight
Price Target: $153
Current: $122.17
Upside: +25.24%
GH Research
Feb 13, 2025
Initiates: Overweight
Price Target: $14
Current: $10.50
Upside: +33.33%
Bright Minds Biosciences
Jan 10, 2025
Initiates: Overweight
Price Target: n/a
Current: $34.50
Upside: -
Biohaven
Dec 17, 2024
Reiterates: Overweight
Price Target: n/a
Current: $29.86
Upside: -
Stoke Therapeutics
Dec 10, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.01
Upside: -
Harmony Biosciences Holdings
Oct 30, 2024
Maintains: Overweight
Price Target: $51 → $58
Current: $33.67
Upside: +72.26%
Alkermes
Oct 25, 2024
Maintains: Overweight
Price Target: $48 → $43
Current: $34.35
Upside: +25.18%
Cytokinetics
Oct 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $43.43
Upside: -
Sep 30, 2024
Reiterates: Overweight
Price Target: n/a
Current: $15.27
Upside: -
Sep 20, 2024
Reiterates: Overweight
Price Target: $130
Current: $131.24
Upside: -0.94%
Sep 16, 2024
Reiterates: Overweight
Price Target: $155
Current: $113.04
Upside: +37.12%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.92
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $3.74
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $35
Current: $16.69
Upside: +109.71%
Aug 1, 2024
Maintains: Overweight
Price Target: $11 → $13
Current: $4.85
Upside: +168.04%
Jul 31, 2024
Reiterates: Overweight
Price Target: n/a
Current: $7.29
Upside: -
Jul 30, 2024
Downgrades: Neutral
Price Target: n/a
Current: $0.43
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $6.83
Upside: -
Jun 21, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.51
Upside: -
Mar 22, 2024
Reiterates: Overweight
Price Target: $34
Current: $21.96
Upside: +54.83%
Oct 24, 2023
Assumes: Overweight
Price Target: $52 → $50
Current: $33.28
Upside: +50.24%
Sep 22, 2023
Initiates: Overweight
Price Target: $5
Current: $5.42
Upside: -7.75%
Sep 7, 2023
Reiterates: Overweight
Price Target: $4
Current: $0.47
Upside: +751.43%
Aug 22, 2023
Reiterates: Overweight
Price Target: $4
Current: $1.39
Upside: +187.77%
Aug 22, 2023
Reiterates: Overweight
Price Target: $58
Current: $36.50
Upside: +58.90%
Aug 22, 2023
Reiterates: Overweight
Price Target: $110
Current: $1.19
Upside: +9,143.70%
Aug 16, 2023
Reiterates: Overweight
Price Target: $80
Current: $4.58
Upside: +1,646.72%
Aug 14, 2023
Reiterates: Overweight
Price Target: $3
Current: $1.17
Upside: +157.51%
Dec 6, 2022
Downgrades: Neutral
Price Target: $16 → $11
Current: $8.67
Upside: +26.87%
Nov 22, 2022
Upgrades: Overweight
Price Target: $9 → $12
Current: $6.88
Upside: +74.42%
Jun 8, 2022
Maintains: Overweight
Price Target: $146 → $168
Current: $8.34
Upside: +1,914.39%
Feb 18, 2022
Initiates: Overweight
Price Target: $20
Current: $2.57
Upside: +678.21%
Feb 18, 2022
Initiates: Overweight
Price Target: $200
Current: $15.39
Upside: +1,199.50%
Apr 20, 2021
Downgrades: Neutral
Price Target: $8 → $4
Current: $0.52
Upside: +669.97%
Oct 23, 2020
Initiates: Overweight
Price Target: $24
Current: $2.81
Upside: +754.09%
Sep 28, 2020
Downgrades: Neutral
Price Target: $372 → $144
Current: $1.95
Upside: +7,284.62%
Jun 1, 2020
Maintains: Overweight
Price Target: $3 → $4
Current: $1.73
Upside: +131.21%
May 19, 2020
Reiterates: Overweight
Price Target: $408 → $480
Current: $4.92
Upside: +9,656.10%
May 4, 2020
Reiterates: Overweight
Price Target: $35 → $39
Current: $60.98
Upside: -36.04%
Feb 21, 2020
Reiterates: Neutral
Price Target: $14 → $15
Current: $55.40
Upside: -72.92%
Nov 15, 2017
Upgrades: Overweight
Price Target: n/a
Current: $1.04
Upside: -
Oct 9, 2017
Initiates: Overweight
Price Target: $180
Current: $5.57
Upside: +3,131.60%